BioSpace News Archive

Liminal BioSciences Announces Sale of Priority Review Voucher for USD105M

Liminal BioSciences Inc., announced today that, its subsidiary Prometic Biotherapeutics Inc. has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (“PRV”) for USD105M.

August 9, 2021
·
10 min read
Pharm Country

Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn’s Disease, Hematology, Pancreatic Cancer and COVID-19

Cytocom Inc. today provided an update regarding its portfolio of clinical programs.

August 9, 2021
·
8 min read
Business

Epizyme Reports Second Quarter 2021 Financial Results and Provides Business Update

Epizyme today reported its second quarter 2021 financial results and provided a business update.

August 9, 2021
·
18 min read
Memory Treatment Centers is One of First to Administer Aduhelm Alzheimer’s Infusion

Memory Treatment Centers, a PURE Healthcare company (PURE), is excited to announce the completion of their first Aduhelm infusion. Memory Treatment Centers are among the first organizations to administer the new FDA approved Alzheimer’s drug, Aduhelm.

August 9, 2021
·
2 min read
Genetown

Inflammasome Therapeutics to Develop Dual Sustained-Release HIV Prevention and Birth Control Implant

Inflammasome Therapeutics, a private, science-based company developing therapies for prevalent, degenerative diseases and sustained-release drug delivery systems, announced it has been awarded a second grant from the Bill & Melinda Gates Foundation.

August 9, 2021
·
3 min read
Aurinia Pharmaceuticals to Present at the BTIG Virtual Biotech Conference

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will participate in a fireside chat during the Virtual BTIG Annual Biotech Conference on Tuesday, August 10, 2021 at 2:50 p.m. ET.

August 9, 2021
·
1 min read
Pharm Country

Aquestive Therapeutics Negotiates Six Month Extension to June 30, 2022 for Additional Libervant™ Related Capital Under Current Debt Agreement

Aquestive Therapeutics, Inc. (NASDAQ: AQST), announced today that it has reached an agreement with its lenders to amend the base indenture providing an extension of the term by six months to June 30, 2022 to provide additional debt in the aggregate of up to $30.0 million.

August 9, 2021
·
8 min read
Business

Rubius Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today reported second quarter 2021 financial results and provided a business update.

August 9, 2021
·
17 min read